Howard S.  Hochster, MD, FACP

Howard S. Hochster, MD, FACP

Rutgers Cancer Institute of New Jersey

Professor of Medicine Associate Director for Clinical Research and Director, GI Oncology, Rutgers Cancer Institute Director of Oncology Research, RWJBarnabas Health

Expertise: OncologyMedical Oncologycancer clinical research

After graduating from the Yale School of Medicine, I completed an internship, residency and fellowship in Hematology-Oncology at Bellevue Hospital and NYU Medical Center. These experiences taught me that the key to success in medicine is to be patient focused and put the patient’s needs first - values that I continue to hold and practice every day. I am certified in Internal Medicine by the American Board of Internal Medicine, and by the Hematology and Oncology Boards. Since 1986, I was on the NYU faculty in medical oncology, rising to full professor before moving to the Yale Cancer Center in 2010, where I was the Associate Director for Clinical Research and head of GI Oncology until joining Rutgers Cancer Institute.

My clinical expertise and research interests are dedicated to early drug development and clinical pharmacology, focused on tumors of the gastrointestinal tract. I have led numerous clinical trials and have been at the forefront of clinical research in GI Oncology and have been instrumental in the approval of eight new drugs for the treatment of colon cancer. I have authored more than 150 peer-reviewed articles on cancer therapy, new drug development and clinical trials and have presented many of these study results at national meetings. I have had two R01 funded research projects on cancer pharmacodynamics and was recently awarded a Lead Academic Participating Site Grant to support NCI sponsored clinical trials. I also have been very involved with the NCI National Clinical Trials Network (NCTN) and have chaired ten phase 2 and phase 3 studies in the NCI cooperative groups. Since 2013, I have chaired the GI Cancer Committee for SWOG (formerly, Southwestern Oncology Group), one of the four NCTN cooperative groups. Together with my SWOG and NCTN colleagues, we strive to design and conduct the studies that set standards of care for pioneering new treatments in cancer care.

Other professional activities include reviewing scientific publications and grant applications in my capacity as Associate Editor for the Journal of the National Cancer Institute and Journal of GI Oncology. I also regularly review manuscripts for Journal of Clinical Oncology, Cancer, British Medical Journal and Lancet. I review grants for the NCI and the Cancer Prevention and Research Institute of Texas. I am also a Medical Director of the Chemotherapy Foundation. In my free time, I am an avid marathon runner and century cyclist.

Rutgers Cancer Institute has a rich history of conducting innovative and groundbreaking cancer research, and, together with RWJBarnabas Health, we offer unparalleled knowledge, clinical care and resources for cancer patients and their families close to home. I feel privileged to work alongside the many expert cancer providers and compassionate staff. Our overall mission is to deliver outstanding cancer care and to achieve the best outcomes for our patients in New Jersey and beyond. My vision is to bring the very best in treatment via clinical trials and clinical research to the people of New Jersey and to make us a treatment destination venue for patients around the world.

Associate Director for Clinical Research at the Rutgers Cancer Institute of New Jersey
Chief, GI Medical Oncology
Director of Cancer Clinical Research, Oncology Service Line, RWJBarnabas

Clinical Expertise:
GI Cancers, colon cancer, pancreatic cancer, biliary cancers, neuroendocrine tumors

Fullbright Scholar (Brussels, Belgium), 1985-6
Best Doctor, New York Magazine or Connecticut Magazine, 1997-2017
America’s Top Doctors, 2003-2017
Top Oncology Doctors in US, 2005-2017
Grant reviewer for NCI and Cancer and Prevention Research Institute of Texas
Chair, New York Cancer Society, 2004-2006
President, International Society of Clinical Oncology, 2017-2019


Cited By


VEGF inhibition and renal thrombotic microangiopathy



Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study



Randomized trial of TAS-102 for refractory metastatic colorectal cancer



A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.



Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma



Cetyxunab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR)



CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts …



Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study



Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with …



Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology



ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.



Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …



Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB …



Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III …



Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology



Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer



NCCN guidelines insights: colon cancer, version 2.2018



Cancer stem cells: the promise and the potential



Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma



A phase II study of taxol in patients with malignant melanoma



"We used a flexible, real-world design for eligibility after first-line chemotherapy. Our results are similar to the reported improvement in progression-free survival in other second-line anti-VEGF trials and supports the fact that antibodies against these two targets can be combined for additional benefit in the appropriate patient population".

- Exploring Targeted Second-Line Therapy for Advanced Colorectal Cancer

Available for logged-in users onlyLogin HereorRegister